论文部分内容阅读
目的观察替吉奥胶囊联合奥沙利铂治疗老年进展期胃癌的临床疗效及安全性。方法将老年进展期胃癌患者86例随机分为观察组和对照组各43例。观察组给予替吉奥胶囊(S-1)联合奥沙利铂治疗,对照组给予5-氟尿嘧啶(5-Fu)联合顺铂治疗,比较2组的临床疗效及不良反应。结果观察组临床受益率(CBR)和疾病进展时间(TTP)高于/长于对照组,差异均有统计学意义(P<0.05);2组有效率(RR)比较差异无统计学意义(P>0.05);观察组白细胞减少、恶心呕吐及手足综合征发生率低于对照组,差异有统计学意义(P<0.05),2组贫血、血小板减少、腹泻及外周神经炎发生率比较差异均无统计学意义(P>0.05)。结论替吉奥胶囊联合奥沙利铂治疗老年晚期胃癌临床疗效好,不良反应发生率低,耐受性好,值得深入研究并在临床推广应用。
Objective To observe the clinical efficacy and safety of tigeo capsule combined with oxaliplatin in the treatment of advanced gastric cancer. Methods 86 cases of advanced gastric cancer patients were randomly divided into observation group and control group, 43 cases each. The observation group was treated with tegaserod (S-1) combined with oxaliplatin and the control group with 5-fluorouracil (5-Fu) combined with cisplatin. The clinical efficacy and adverse reactions of the two groups were compared. Results The clinical benefit rate (CBR) and disease progression time (TTP) in the observation group were both higher than those in the control group (P <0.05). There was no significant difference in the effective rate (RR) between the two groups > 0.05). The incidences of leukopenia, nausea and vomiting and hand-foot syndrome in the observation group were lower than those in the control group (P <0.05), and the incidences of anemia, thrombocytopenia, diarrhea and peripheral neuritis in the two groups were significantly different No statistical significance (P> 0.05). Conclusion The treatment of geggio capsules combined with oxaliplatin in elderly patients with advanced gastric cancer has good clinical efficacy, low incidence of adverse reactions and good tolerance, which deserves further study and clinical application.